Huntington’s disease Market
Nov 24, 2025
Huntington’s Disease Treatment Meets Its Match: Gene Therapy in Action
Huntington’s Disease: Genetics, Symptoms, and Therapeutic Gaps Huntington’s disease is often described as having Amyotrophic Lateral Sclerosis (ALS), Parkinson’s, and Alzheimer’s rolled into one—a neurodegenerative triple threat that devastates motor control, cognition, and behavior in a single blow. Caused by t...
Read More...
Apr 22, 2025
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New CSU Therapy in Over a Decade; Gilead’s TRODELVY + KEYTRUDA Shows PFS Benefit in PD-L1+ TNBC; Tempest’s TPST-1495 Gets FDA Orphan Tag for FAP; uniQure’s AMT-130 Granted FDA Breakthrough for Huntington’s; NeuroNOS’ BA-102 Secures FDA Orphan Status for Phelan-McDermid Syndrome
FDA Approves Sanofi/Regeneron’s DUPIXENT as First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria Regeneron Pharmaceuticals and Sanofi have announced that the FDA has approved DUPIXENT (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous...
Read More...
Sep 18, 2023
A Turning Point: INGREZZA’s Impact on Huntington’s Disease Treatment and the Rise of Novel Therapies
Huntington’s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United States have Huntington’s disease, and another 200,000 are at risk of developing the condition. As per DelveInsight analy...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
